PACIRA BIOSCIENCES INC

PCRXNASDAQ

🏆 #2222 by market capEarnings Nov 5US Equity

$24.02▼ $0.35 (−1.46%)

Live

1h▼ 0.6%

24h▼ 1.5%

7d▼ 3.3%

14d▼ 9.1%

30d▼ 5.9%

1y▼ 3.1%

🏦Market Cap

$945M

Small Cap

📈Revenue Growth (YoY)

+5.7%

Slowing

📊Gross Margin

79.2%

High

💵FCF Margin

24.1%

Strong

⚖️P/S Ratio

1.3x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $23.78 – $24.16
52-Week Range: $18.80 – $27.66
Volume: $1.93B
Avg Volume: $2.27B
Shares Outstanding: 39.4M
Next Earnings: Sep 17, 2026

Fundamentals Snapshot

Annual Revenue: $726M
Last Q Revenue: $192M
P/E Ratio: 67.1
P/S Ratio: 1.3x
EPS (TTM): $0.35
Dividend Yield: —

Why Investors Own PCRX

✓High-growth profile — revenue up +4.4% YoY with expanding US Equity exposure.
✓Healthy economics — 75% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$726M▲ +7.1% YoY

Gross Margin (TTM)

75.2%▲ +0.7% YoY

Operating Income (TTM)

$173M▲ +7.1% YoY

Free Cash Flow (TTM)

$161M▲ +7.1% YoY

About PACIRA BIOSCIENCES INC

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

🦦